9 results on '"Bolwell, Brian J."'
Search Results
2. Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
- Author
-
Bejanyan, Nelli, Bolwell, Brian J., Lazaryan, Aleksandr, Rybicki, Lisa, Tench, Shawnda, Duong, Hien, Andresen, Steven, Sobecks, Ronald, Dean, Robert, Pohlman, Brad, Kalaycio, Matt, and Copelan, Edward A.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HOSPITAL admission & discharge , *MEDICARE , *ANALYSIS of variance , *GRAFT versus host disease , *BONE marrow - Abstract
Patient readmission within 30 days from discharge has been perceived by the Centers for Medicare and Medical Services as an indicator of poor healthcare quality for specific high-cost medical conditions. Patients who undergo allogeneic hematopoietic cell transplantation (allo-HCT) are often being readmitted. Our study identified the risk factors for 30-day readmission among 618 adult recipients of myeloablative allo-HCT from 1990 to 2009. Two hundred forty-two (39%) of 618 patients (median age = 42 years [range: 18-66]) were readmitted a median of 10 days (range: 1-30) from their hospital discharge. Median duration of readmission was 8 days (range: 0-103). Infections (n = 68), fever with or without identified source of infection (n = 63), gastrointestinal complications (n = 44), graft-versus-host disease (GVHD) (n = 38), and other reasons (n = 29) accounted for 28%, 26%, 18%, 16%, and 12% of readmissions, respectively. During their index admission, patients who were subsequently readmitted had more documented infections (P < .001), higher hematopoietic cell transplantation comorbidity index (HCT-CI) (P < .01), total body irridiation (TBI)-based conditioning (P < .001), unrelated donor (P < .001), and peripheral stem cell (P = .014) transplantation. In multivariable analysis, HCT-CI (odds ratio [OR] = 1.78; 95% confidence interval [CI], 1.25-2.52), TBI-based preparative regimen (OR = 2.63; 95% CI, 1.67-4.13), and infection during admission for allo-HSCT (OR = 2.00; 95% CI, 1.37-2.92) predicted 30-day readmission. Thirty-day readmission itself was an independent predictor of all-cause mortality (hazard ratio [HR]Adj = 1.66; 95% CI, 1.36-2.10). Our data emphasize the importance of a risk-standardized approach to 30-day hospital readmission if it is used as a quality-of-care metric for bone marrow transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. Nonmyeloablative Second Transplants are Associated with Lower Nonrelapse Mortality and Superior Survival Than Myeloablative Second Transplants
- Author
-
Hill, Brian T., Bolwell, Brian J., Rybicki, Lisa, Dean, Robert, Kalaycio, Matt, Pohlman, Brad, Tench, Shawnda, Sobecks, Ronald, Andresen, Steven, and Copelan, Edward
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HEALTH outcome assessment , *MEDICAL care , *PROGNOSIS , *GRAFT versus host disease - Abstract
Allogeneic hematopoietic stem cell transplantation (SCT) for patients who have previously undergone allogeneic or autologous SCT is potentially curative, but dangerous. To identify patient, disease, and treatment characteristics associated with outcome, we analyzed prognostic factors in 98 consecutive patients who underwent second transplants using allogeneic donors at the Cleveland Clinic between May 1987 and October 2008. Inclusion criteria included age ≥18 years, first SCT either autologous or allogeneic, and second SCT allogeneic. Patients whose second transplant was myeloablative (MA) had shorter survival (median 3.2 versus 14.7 months, P < .001) than patients whose second transplant was nonmyeloablative (NMA). In multivariable analysis, MA second transplant was associated with a higher risk of NRM (hazard ratio [HR] 2.01, P = 0.022) and death (HR 2.13, P = 0.002). Improved survival after NMA second transplant occurred primarily in patients without acute leukemia and when the first transplant was allogeneic. Among 17 patients transplanted within 3 months of first transplant, mortality was 100% and median survival was 2.3 months. MA transplantation within 3 months of prior SCT carries an unacceptably high rate of NRM. NMA second transplants were associated with substantially less NRM and despite a higher incidence of relapse, significantly improved survival compared to MA second transplants. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
4. High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation
- Author
-
Blum, William, Bolwell, Brian J., Phillips, Gary, Farag, Sherif S., Lin, Thomas S., Avalos, Belinda R., Penza, Sam L., Marcucci, Guido, Byrd, John C., Kalaycio, Matt E., Sobecks, Ronald M., Pohlman, Brad, Brown, Stacey, Elder, Patrick J., and Copelan, Edward A.
- Subjects
- *
GRAFT versus host disease , *CELL transplantation , *MYELOID leukemia , *ANEMIA - Abstract
Abstract: Results were analyzed for 48 consecutive patients with acute myeloid leukemia not in remission who underwent unrelated donor bone marrow or stem cell transplantation between 1991 and February 2003 at 2 transplant centers. Forty-six were adults with a median age of 32 years (range, 4-58 years). Forty-two were HLA-A, -B, and -DR matched with their respective donors, and 6 were mismatched at 1 of these loci. The conditioning regimen was myeloablative in all cases: busulfan/cyclophosphamide/etoposide in 34 patients, busulfan/cyclophosphamide in 10 patients, and total body irradiation based in 4 patients. Median follow-up for survivors was 540 days (range, 145-2716 days). Only patients with <5000 peripheral blood blasts per microliter at the time of transplantation survived 2 years (18% versus 0%; P = .003). Similarly, patients with <20% blasts in the marrow at the time of transplantation had superior 2-year survival compared with those who had ≥20% (33% versus 5%; P = .04). Patients with <20% blasts who had ≥3 prior therapies also fared poorly. Cause of death was more commonly treatment related rather than relapse related. This study confirms that patients with acute myeloid leukemia not in remission can achieve prolonged survival with myeloablative conditioning and unrelated donor cell transplantation. However, sustained survival occurs only in patients with a low disease burden at the time of unrelated donor stem cell transplantation, and patients with a high disease burden may benefit from added counseling regarding the high risk of death due to both treatment-related toxicities and disease relapse. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
5. Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort.
- Author
-
Arora, Mukta, Hemmer, Michael T., Kwang Woo Ahn, Klein, John P., Cutler, Corey S., Urbano-Ispizua, Alvaro, Couriel, Daniel R., Alousi, Amin M., Gale, Robert Peter, Yoshihiro Inamoto, Weisdorf, Daniel J., Peigang Li, Antin, Joseph H., Bolwell, Brian J., Boyiadzis, Michael, Cahn, Jean-Yves, Cairo, Mitchell S., Isola, Luis M., Jacobsohn, David A., and Jagasia, Madan
- Subjects
- *
BONE marrow transplantation , *GRAFT versus host disease , *HEALTH outcome assessment , *HEMATOPOIETIC stem cell transplantation , *DISEASE incidence - Abstract
We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all P < .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
- Author
-
Jagasia, Madan, Arora, Mukta, Flowers, Mary E. D., Chao, Nelson J., McCarthy, Philip L., Cutler, Corey S., Urbano-Ispizua, Alvaro, Pavletic, Steven Z., Haagenson, Michael D., Mei-Jie Zhang, Antin, Joseph H., Bolwell, Brian J., Bredeson, Christopher, Cahn, Jean-Yves, Cairo, Mitchell, Gale, Robert Peter, Gupta, Vikas, Lee, Stephanie J., Litzow, Mark, and Weisdorf, Daniel J.
- Subjects
- *
DISEASE risk factors , *GRAFT versus host disease , *BONE marrow diseases , *CELL transplantation , *BONE grafting , *GENETICS , *THERAPEUTICS - Abstract
Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen on AGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PBSCs had lower risks of grades B-D AGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.
- Author
-
Jacobsohn, David A., Arora, Mukta, Klein, John P., Hassebroek, Anna, Flowers, Mary E., Cutler, Corey S., Urbano-lspizua, Alvaro, Bolwell, Brian J., Antin, Joseph H., Boyiadzis, Michael, Cahn, Jean-Yves, Cairo, Mitchell S., Herzig, Roger H., Isola, Luis M., Klumpp, Thomas A., Lee, Stephanie J., Petersdorf, Effie W., Santarone, Stella, Gale, Robert P., and Schouten, Harry C.
- Subjects
- *
GRAFT versus host disease , *DISEASE relapse , *MORTALITY , *MULTIVARIATE analysis , *LEUKEMIA in children , *MYELODYSPLASTIC syndromes - Abstract
There is a paucity of information regarding the factors that affect nonrelapse mortality (NRM) and overall survival among children that develop chronic graftversus-host disease (cGVHD). We performed multivarlate analyses using data from the Center for International Rlood and Marrow Transplant Research to identify risk factors for NF1M and survival In 1117 pediatrIc subjects with leukemia or myelodysplastic syndrome, transplanted from related donors, unrelated donors (URD), or unrelated cord blood between 1995 and 2004. We identified 4 variables associated with higher NHM: HLA partially matched or mismatched URD, peripheral blood cell graft, Karnotsky/ Lansky score <80 at cGVHD diagnosis, and platelets < 100 x 109/L at cGVHD diagnosis. Factors associated with significantly worse survival were: age> 10 years, transplantation from HLA partially matched or mismatched URD, advanced disease at transplantation, Karnofskyl Lansky < 80; and platelets < 100 x 10~JL. Cumulative incidence of discontinuation of systemic immune suppression at 1, 3, and 5 years after diagnosis of cGVHD were 22% (20%..25%), 34°o (31%37%), and 37% (34%40%), respectively. This Is the largest study elucidating variables affecting outcome after diagnosis of cGVl-ID In pediatric allograft recipients. These variables may be useful for risk stratification, development of future clinical trials, and family counseling In children with cGVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
8. Outcome of Transplantation for Myelofibrosis
- Author
-
Ballen, Karen K., Shrestha, Smriti, Sobocinski, Kathleen A., Zhang, Mei-Jie, Bashey, Asad, Bolwell, Brian J., Cervantes, Francisco, Devine, Steven M., Gale, Robert Peter, Gupta, Vikas, Hahn, Theresa E., Hogan, William J., Kröger, Nicolaus, Litzow, Mark R., Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Schiller, Gary, Schouten, Harry C., and Roy, Vivek
- Subjects
- *
MYELOFIBROSIS , *STEM cell transplantation , *HEMATOPOIETIC stem cells , *HOMOGRAFTS , *HLA histocompatibility antigens , *GRAFT versus host disease , *THERAPEUTICS - Abstract
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
9. ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited
- Author
-
Seebach, Jörg D., Stussi, Georg, Passweg, Jakob R., Loberiza, Fausto R., Gajewski, James L., Keating, Armand, Goerner, Martin, Rowlings, Philip A., Tiberghien, Pierre, Elfenbein, Gerald J., Gale, Robert Peter, van Rood, Jon J., Reddy, Vijay, Gluckman, Eliane, Bolwell, Brian J., Klumpp, Thomas R., Horowitz, Mary M., Ringdén, Olle, and Barrett, A. John
- Subjects
- *
BONE marrow transplantation , *IMMUNE system , *LEUKEMIA , *GRAFT versus host disease - Abstract
Abstract: Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone marrow transplantation (BMT). These studies, however, included small and heterogenous study populations, and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial, we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A total of 2108 (67.9%) donor-recipient pairs were ABO identical, 451 (14.5%) had a minor mismatch, 430 (13.9%) had a major mismatch, and 114 (3.7%) had a bidirectional ABO mismatch. The groups did not differ significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirectional ABO mismatch group (P = .017). In multivariate models of overall survival, transplant-related mortality, and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869; 95% confidence interval, 1.192-2.93; P = .006). Patients with major ABO mismatch received red blood cell transfusions (P = .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery (P < .001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome of conventional BMT among patients with leukemia. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.